Akeso enrolls first patient in global Phase III cadonilimab vs nivolumab trial in first-line gastric cancer

• Akeso enrolled the first patient in COMPASSION-37, a global Phase III trial in first-line HER2-negative advanced gastric or GEJ cancer.
• Cadonilimab with chemotherapy will be tested head-to-head against chemotherapy with or without nivolumab, targeting standard-of-care positioning.
• No results were reported; the study is designed to determine whether dual PD-1/CTLA-4 blockade improves outcomes, including in PD-L1-low disease.
• Prior Phase III results from China’s COMPASSION-15 were already presented, supporting a survival benefit across PD-L1 expression levels without detailing metrics.
• The program extends cadonilimab’s strategy from China approvals into global validation, with broader registrational development across major tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609272205PR_NEWS_USPR_____CN57707) on September 28, 2026, and is solely responsible for the information contained therein.